Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Indian chess player R Vaishali has scripted the history by winning the Women's Candidates Tournament…
Maharashtra is one of the most important states of India. It is famous for its…
Unemployment rate of India has climbed to 5.1% in the Month of the March 2026.…
The awaited TIME100 list for 2026 has been officially released by the TIME. This reports…
India has many beautiful valleys filled with greenery, rivers, and mountains. Some of these valleys…
Federation of Indian Chambers of Commerce and Industry (FICCI) has appointed the Anant Swarup as…